← All candidates
19 insider filings on record.
19 filings on record.
DMRADamora Therapeutics, Inc.
NasdaqCM · Healthcare · $1.73B
$28.39
+1.03% · Sep 14
19 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 4 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what DMRA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.73B
Float
41.4M
67% public
Short % float
Pro
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
14 more transactions on Pro →Context
Wall St
$43.38 avg target
+52.8% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 1 quarters beat
Q3 '25−$2.36 act
Coverage
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeMotley Fool · 05-30What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For ShareholdersSimply Wall St. · 05-08Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerInsider Monkey · 05-05Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price MomentumSimply Wall St. · 05-05
The file stays open
19 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice